Year: 2022

news_6

InnoCare Announces the Acceptance of the Biologics License Application for Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969) announced today the acceptance of the biologics license application (BLA) for tafasitamab in combination with...

logo-135

Japan Biotech Startups Directory 2021-2022: Profiles of 395 Companies with Outstanding Technologies and Business Models – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "The Directory of Biotech Startups in Japan 2021-2022" directory has been added to ResearchAndMarkets.com's offering. This report is...